Drug intelligence / Profile preview

corticotropin + methotrexate

Development stage: Unknown
Lead developer: Mallinckrodt
Modality: Small Molecules
Administration: Intramuscular, Oral, Subcutaneous

Overview

A combination therapy consisting of corticotropin (ACTH) and methotrexate. This combination has been studied for the treatment of newly diagnosed rheumatoid arthritis patients. Methotrexate is a first-line disease-modifying antirheumatic drug (DMARD) that reduces inflammation, pain, and slows joint damage by inhibiting dihydrofolate reductase and affecting multiple inflammatory pathways. Corticotropin is a hormone that stimulates the adrenal cortex to produce cortisol and other steroid hormones, providing additional anti-inflammatory effects.

Other names: ACTH + methotrexate

Targets

HMGB1 (High mobility group protein B1)DHFR (Dihydrofolate reductase)IL1B (Interleukin-1 beta)MC2R (Adrenocorticotropic Hormone Receptor)

Beyond the preview

Go deeper on corticotropin + methotrexate.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on corticotropin + methotrexate.

Explore the full profile